Back to Results

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A 0201-positive Patients with Advanced MAGE-A4-positive Cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Breelyn Wilky,  MD

Breelyn Wilky, MD

Study ID

Protocol Number: 19-2311

More information available at ClinicalTrials.gov: NCT03973333

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers